Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
18.36
Dollar change
-0.17
Percentage change
-0.92
%
Index- P/E- EPS (ttm)-2.56 Insider Own64.76% Shs Outstand52.29M Perf Week3.61%
Market Cap988.14M Forward P/E- EPS next Y-2.78 Insider Trans0.00% Shs Float18.96M Perf Month-2.13%
Income-115.13M PEG- EPS next Q-0.59 Inst Own30.94% Short Float0.73% Perf Quarter-12.57%
Sales0.00M P/S- EPS this Y13.97% Inst Trans-0.09% Short Ratio1.96 Perf Half Y-34.08%
Book/sh7.21 P/B2.55 EPS next Y-12.16% ROA-40.51% Short Interest0.14M Perf Year19.61%
Cash/sh7.39 P/C2.48 EPS next 5Y20.59% ROE-43.59% 52W Range14.05 - 33.00 Perf YTD-34.55%
Dividend Est.- P/FCF- EPS past 5Y-28.27% ROI-29.67% 52W High-44.36% Beta-3.10
Dividend TTM- Quick Ratio20.53 Sales past 5Y0.00% Gross Margin- 52W Low30.69% ATR (14)1.34
Dividend Ex-Date- Current Ratio20.53 EPS Y/Y TTM-0.13% Oper. Margin0.00% RSI (14)50.66 Volatility6.34% 7.97%
Employees82 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.43 Target Price33.08
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q21.19% Payout- Rel Volume0.28 Prev Close18.53
Sales Surprise- EPS Surprise6.79% Sales Q/Q- EarningsMay 08 AMC Avg Volume70.09K Price18.36
SMA201.17% SMA50-3.17% SMA200-16.80% Trades Volume19,766 Change-0.92%
Date Action Analyst Rating Change Price Target Change
Sep-25-23Initiated Wedbush Outperform $27
Aug-15-23Upgrade Morgan Stanley Equal-Weight → Overweight $10 → $34
Oct-05-22Initiated Bryan Garnier Buy $16
Sep-13-22Resumed JMP Securities Mkt Outperform $34 → $18
Aug-23-22Downgrade Morgan Stanley Overweight → Equal-Weight $40 → $10
Aug-22-22Downgrade BofA Securities Neutral → Underperform $26 → $13
May-25-22Initiated JMP Securities Mkt Outperform $34
Mar-02-21Initiated SVB Leerink Outperform $50
Mar-02-21Initiated Oppenheimer Outperform $48
Mar-02-21Initiated Morgan Stanley Overweight $51
Jul-16-24 04:02PM
11:55AM
Jun-11-24 06:50AM
Jun-04-24 06:50AM
May-13-24 06:50AM
11:55PM Loading…
May-08-24 11:55PM
04:10PM
Apr-10-24 09:52PM
04:10PM
04:08PM
Apr-04-24 06:50AM
Mar-18-24 06:50AM
Mar-06-24 06:50AM
Mar-05-24 06:50AM
Feb-22-24 06:50AM
06:50AM Loading…
Feb-16-24 06:50AM
Jan-26-24 06:50AM
Jan-23-24 09:34AM
Jan-22-24 04:07PM
07:34AM
06:50AM
Jan-05-24 06:50AM
Dec-08-23 06:00PM
Dec-07-23 03:17PM
Dec-06-23 10:16AM
09:33AM
07:02AM
06:56AM
06:50AM
Nov-30-23 06:50AM
06:50AM Loading…
Nov-15-23 06:50AM
Nov-09-23 11:00AM
Nov-02-23 06:50AM
Oct-30-23 06:50AM
Oct-13-23 06:50AM
Oct-04-23 07:34AM
Sep-19-23 06:50AM
Sep-06-23 06:51AM
06:50AM
Aug-31-23 08:09PM
Aug-23-23 06:50AM
Aug-15-23 09:59AM
Aug-07-23 06:50AM
Jul-21-23 10:20AM
Jul-03-23 08:16AM
Jun-27-23 12:11PM
Jun-26-23 02:27PM
06:50AM
Jun-20-23 06:50AM
Jun-10-23 06:01PM
Jun-01-23 06:50AM
May-17-23 09:55AM
May-08-23 06:50AM
May-06-23 01:00PM
Apr-05-23 06:51AM
Mar-20-23 03:31PM
Mar-18-23 12:35AM
Mar-02-23 06:50AM
Feb-24-23 06:50AM
Feb-08-23 06:50AM
Jan-24-23 05:36AM
Jan-09-23 06:50AM
Dec-08-22 01:15PM
06:51AM
06:50AM
Nov-10-22 08:00AM
Oct-11-22 02:27PM
Oct-07-22 08:30AM
Sep-30-22 06:50AM
Sep-16-22 04:45AM
Sep-12-22 06:50AM
Aug-22-22 04:09PM
03:45PM
06:50AM
Jul-14-22 08:10AM
Jul-06-22 08:10AM
Jun-14-22 08:10AM
Jun-07-22 08:10AM
May-16-22 08:10AM
May-11-22 08:15AM
08:10AM
May-05-22 04:10PM
May-04-22 01:14PM
Apr-06-22 04:10PM
Mar-29-22 08:10AM
Mar-22-22 08:10AM
Mar-03-22 08:00AM
Feb-25-22 09:40AM
Feb-09-22 08:10AM
Jan-26-22 09:40AM
Dec-22-21 08:10AM
Dec-07-21 08:10AM
Nov-10-21 08:10AM
Nov-08-21 05:51AM
Nov-02-21 02:00PM
Sep-03-21 08:00AM
Jul-30-21 08:00AM
Jul-09-21 06:10PM
Jul-01-21 07:00AM
Jun-11-21 08:00AM
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.